Skip to content

Inspiratory and Expiratory Muscle Training in Adolescent Volleyball Players

Effects of Inspiratory and Expiratory Muscle Strength Training on Respiratory Functions and Performance in Adolescent Volleyball Players

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06759779
Enrollment
26
Registered
2025-01-06
Start date
2023-07-01
Completion date
2025-03-01
Last updated
2025-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adolescent Development

Keywords

pulmonary functions, muscle training, adolescent health, volleyball players

Brief summary

This study will investigate the effects of inspiratory and expiratory muscle training on respiratory muscle strength, pulmonary function, and performance status in adolescent athletes

Detailed description

In the literature, it has been shown in a limited number of studies that respiratory muscle training in sports such as football, cycling, swimming, and rugby reduces athletes' perceived exertion levels. However, the effects of inspiratory and expiratory muscle training on respiratory muscle strength, pulmonary function, and performance status in adolescent athletes are still unclear. Therefore, this study has been planned.

Interventions

DEVICEinspiratory muscle training

Inspiratory muscle training will be performed

Expiratory muscle training will be performed

Sponsors

Gazi University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
12 Years to 18 Years
Healthy volunteers
Yes

Inclusion criteria

* Athletes aged 12-18 who train at a submaximal level at least 3 days a week

Exclusion criteria

* Adolescents with any history of chronic lung disease * unable to comply with the test and training * unwilling to participate in the study

Design outcomes

Primary

MeasureTime frameDescription
Respiratory muscle strengthFirst dayMaximal inspiratory and expiratory muscle strength will be evaluated using mouth pressure device .

Secondary

MeasureTime frameDescription
FEV1First dayulmonary function tests will be performed using a spirometry according to the American Thoracic Society and European Respratory Society criteria. FEV1 will be evaluated. The percentage of predicted value \<70% will be expressed as abnormal
FVCFirst dayulmonary function tests will be performed using a spirometry according to the American Thoracic Society and European Respratory Society criteria. FEV1 will be evaluated. The percentage of predicted value \<70% will be expressed as abnormal
FEV1/FVCFirst dayPulmonary function tests will be performed using a spirometry according to the American Thoracic Society and European Respratory Society criteria. FEV1/FVC will be evaluated.
PEFFirst dayPulmonary function tests will be performed using a spirometry according to the American Thoracic Society and European Respratory Society criteria. PEF will be evaluated. The percentage of predicted value \<70% will be expressed as abnormal
Constant load-inspiratory muscle endurance testFirst dayIt will be evaluated with inspiratory muscle trainer
Athletic performancesecond dayPerformance will be evaluated with shuttle run test
Fat free mass Body compositionssecond dayFat free mass (kg) will be evaluated with bioelectrical impedance analyzer
Fat mass Body compositionssecond dayFat mass (kg) will be evaluated with bioelectrical impedance analyzer
Fat percentage Body compositionssecond dayFat percentage (%) will be evaluated with bioelectrical impedance analyzer
FEF2575First dayPulmonary function tests will be performed using a spirometry according to the American Thoracic Society and European Respratory Society criteria. FEF2575 will be evaluated. The percentage of predicted value \<50% will be expressed as abnormal

Countries

Turkey (Türkiye)

Contacts

Primary ContactZeliha ÇELİK, Asst.Prof.
zelihacelik1@hotmail.com+90 (358) 218 17 67

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026